Wang IK, Yen TH, Guo YC, et al. - Researchers used the Taiwan Stroke Registry (TSR) data to compare the effectiveness of aspirin, clopidogrel and dual antiplatelet therapy (DAPT) with combination of both aspirin and clopidogrel on the secondary prevention of stroke by estimated glomerular filtration rate (eGFR) levels measured at the time of admission for ischaemic stroke. The re-stroke incidence and 1-year mortality have been stratified by eGFR levels at admission: ≥ 90, 60–89 and < 60 ml/min/1.73 m² or on dialysis. According to findings, the re-stroke differences were not statistically significant for the clopidogrel group and the DAPT group after controlling for the competing risk of death compared with the aspirin group. For ischaemic stroke patients with or without renal dysfunction receiving antiplatelet agents with aspirin, clopidogrel or dual agents combined with aspirin and clopidogrel, there was no difference in the risks of recurrent stroke and 1-year mortality, irrespective of their renal dysfunction status.